Literature DB >> 30298378

I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Frederik A Verburg1, Luca Giovanella2, Ioannis Iakovou3, Mark W Konijnenberg4, Werner Langsteger5, Michael Lassmann6, Jasna Mihailovic7, Markus Luster8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30298378     DOI： 10.1007/s00259-018-4184-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma.

Authors:  S M SEIDLIN; E SIEGAL; A A YALOW; S MELAMED
Journal:  Science       Date:  1956-05-04       Impact factor: 47.728

2.  Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid.

Authors:  S M SEIDLIN; L D MARINELLI; E OSHRY
Journal:  J Am Med Assoc       Date:  1946-12-07

Review 3.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

4.  Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.

Authors:  Frederik A Verburg; Uwe Mäder; Karina Tanase; Elena-Daphne Thies; Stefanie Diessl; Andreas K Buck; Markus Luster; Christoph Reiners
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

5.  Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma.

Authors:  Hester T Prinsen; Esther N Klein Hesselink; Adrienne H Brouwers; John T M Plukker; Wim J Sluiter; Anouk N A van der Horst-Schrivers; Gustaaf W van Imhoff; Thera P Links
Journal:  J Clin Endocrinol Metab       Date:  2015-08-11       Impact factor: 5.958

6.  DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.

Authors:  Uta Eberlein; Harry Scherthan; Christina Bluemel; Michel Peper; Constantin Lapa; Andreas Konrad Buck; Matthias Port; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-11-12       Impact factor: 10.057

7.  Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Authors:  R J Molenaar; C Pleyer; T Radivoyevitch; S Sidana; A Godley; A S Advani; A T Gerds; H E Carraway; M Kalaycio; A Nazha; D J Adelstein; C Nasr; D Angelini; J P Maciejewski; N Majhail; M A Sekeres; S Mukherjee
Journal:  Leukemia       Date:  2017-11-06       Impact factor: 11.528

8.  Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Authors:  Frederik A Verburg; Heribert Hänscheid; Johannes Biko; Maria C Hategan; Michael Lassmann; Michael C Kreissl; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-24       Impact factor: 9.236

9.  Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Authors:  Remco J Molenaar; Surbhi Sidana; Tomas Radivoyevitch; Anjali S Advani; Aaron T Gerds; Hetty E Carraway; Dana Angelini; Matt Kalaycio; Aziz Nazha; David J Adelstein; Christian Nasr; Jaroslaw P Maciejewski; Navneet S Majhail; Mikkael A Sekeres; Sudipto Mukherjee
Journal:  J Clin Oncol       Date:  2017-12-18       Impact factor: 50.717

10.  Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.

Authors:  Alfredo Campennì; Luca Giovanella; Salvatore Antonio Pignata; Antonio Vento; Angela Alibrandi; Letterio Sturiale; Riccardo Laudicella; Alessio Danilo Comis; Rossella Filice; Giuseppe Giuffrida; Maria Elena Stipo; Salvatore Giovinazzo; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Sergio Baldari
Journal:  Oncotarget       Date:  2018-04-03
View more
  4 in total

1.  Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

Authors:  Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03       Impact factor: 9.236

Review 2.  Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach.

Authors:  Marguerite T Parisi; Hedieh Khalatbari; Sanjay R Parikh; Adina Alazraki
Journal:  Pediatr Radiol       Date:  2019-10-16

3.  Guidelines Are Not Gospel!

Authors:  Gilbert H Daniels; Peter A Kopp
Journal:  Thyroid       Date:  2019-06       Impact factor: 6.568

4.  Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.

Authors:  Xiaoran Mei; Xiaoqin Yao; Fang Feng; Weiwei Cheng; Hui Wang
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.